Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NCG7
UPID:
DGLB_HUMAN
Alternative names:
KCCR13L; PUFA-specific triacylglycerol lipase; Sn1-specific diacylglycerol lipase beta
Alternative UPACC:
Q8NCG7; A4D2P3; B3KV90; B4DQU0; Q6PIX3; Q8N2N2; Q8N9S1; Q8TED3; Q8WXE6
Background:
Diacylglycerol lipase-beta (DAGL-beta), known by alternative names such as KCCR13L and PUFA-specific triacylglycerol lipase, is a pivotal enzyme in lipid metabolism. It catalyzes the hydrolysis of arachidonic acid-esterified diacylglycerols to produce 2-arachidonoylglycerol (2-AG), a principal endocannabinoid. This enzyme preferentially targets DAGs at the sn-1 position in a calcium-dependent manner, playing a crucial role in regulating 2-AG and arachidonic acid pools for eicosanoid production via cyclooxygenase pathways.
Therapeutic significance:
Understanding the role of Diacylglycerol lipase-beta could open doors to potential therapeutic strategies, particularly in modulating inflammatory responses and lipid mediator production.